# Moderna Raises Full-Year Growth Outlook to 15% to 25% After Q3 Earnings Beat

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52439
Published: 2026-11-09T17:06:42.000Z
Updated: 2026-11-09T17:06:42.000Z
Section: Business

> Higher overseas COVID-19 vaccine sales drove revenue growth and helped produce the third-quarter earnings beat.

Moderna raised its full-year growth outlook to 15% to 25% after third-quarter results showed revenue growth and an earnings beat. Higher overseas sales of its COVID-19 vaccines drove the revenue growth and helped produce the earnings beat.